MiddleBrook shares soar on FDA's strep therapy OK
Investors cheered the news of the FDA's approval of MiddleBrook Pharma's once-daily, 775 milligram Moxatag Tablets for strep throat by tripling the value of its shares. Its stock soared $2.30 to $3.55, moving the company's capitalization from $58 million to $171 million. A late-stage trial of Moxatag demonstrated that it worked as well as a regimen of penicillin for eradicating bacteria that causes strep. It will soon become the only once-daily amoxicillin therapy on the U.S. market. The approval did come with a catch: MiddleBrook will continue to investigate the drug's impact on children under the age of 12.
- check out the release
- read the AP report
Related Articles:
MiddleBrook lines up $10M in financing. Report
Advancis changes name-again. Report
FDA rejects Advancis' NDA on strep therapy. Report
Comments
Yes, but can a QD pulsatile pill compete with a $4 BID generic from Walmart?
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


